Title |
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/Rmutations
|
---|---|
Published in |
BMC Cancer, January 2013
|
DOI | 10.1186/1471-2407-13-17 |
Pubmed ID | |
Authors |
Giusy Gentilcore, Gabriele Madonna, Nicola Mozzillo, Antoni Ribas, Antonio Cossu, Giuseppe Palmieri, Paolo A Ascierto |
Abstract |
Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 46 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 24% |
Student > Ph. D. Student | 8 | 17% |
Other | 5 | 11% |
Student > Bachelor | 4 | 9% |
Professor > Associate Professor | 3 | 7% |
Other | 4 | 9% |
Unknown | 11 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 13 | 28% |
Medicine and Dentistry | 8 | 17% |
Biochemistry, Genetics and Molecular Biology | 8 | 17% |
Chemistry | 3 | 7% |
Immunology and Microbiology | 2 | 4% |
Other | 1 | 2% |
Unknown | 11 | 24% |